Primary Outcome Measures:
- Evaluation of patients with CNS tumors who are probable future candidates for NCI phase I and II protocols
- Follow patients with CNS tumors that are representative of important scientific and/or clinical principles
- Attain a steady flow of patients with CNS tumors at the NIH, which will help to educate nurses, medical residents, clinical fellows, and others in management and care of this subgroup of cancer patients
OBJECTIVES:
- Evaluate patients with CNS tumors who are probable future candidates for NCI phase I and II protocols.
- Follow patients with CNS tumors that are representative of important scientific and/or clinical principles.
- Attain a steady flow of patients with CNS tumors at the NIH, which will help to educate nurses, medical residents, clinical fellows, and others in management and care of this subgroup of cancer patients.
OUTLINE: Patients receive an initial evaluation by the NCI Neuro-Oncology Branch at the NIH Clinical Center. Patients may choose to end their participation on the study after the initial evaluation or may continue being evaluated at NIH. Generally, patients living in close proximity to the NIH are followed at NIH every 3-6 months. Patients living at a distance from NIH resume standard care with their local physician, but either they are followed periodically at NIH (e.g., if disease progression occurs) or they (and/or their physician) are contacted by the Neuro-Oncology Branch at least every 6 months to generally follow the natural history of the disease and patient outcome.
Patients may undergo any or all of the following procedures at initial or follow-up evaluations: MRI or CT scan, PET scan, blood tests, neurologic exam, and physical exam and history.
PROJECTED ACCRUAL: A total of 3,000 patients will be accrued for this study.
Purpose
